Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement
- PMID: 19620820
- DOI: 10.1007/BF03345773
Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement
Abstract
Objective: Although two studies have shown that Addison's disease (AD) is still a potentially lethal condition for cardiovascular, malignant, and infectious diseases, a recent retrospective study showed a normal overall mortality rate. Differently from secondary hypoadrenalism, scanty data exist on the role of conventional glucocorticoid replacement on metabolic and cardiovascular outcome in AD.
Subjects and methods: In 38 AD under conventional glucocorticoid replacement (hydrocortisone 30 mg/day or cortisone 37.5 mg/day) ACTH, plasma renin activity (PRA), DHEAS, fasting glucose and insulin, 2-h glucose after oral glucose tolerance test, serum lipids, 24-h blood pressure and intima-media thickness (IMT) were evaluated and compared with 38 age-, sex- and body mass index (BMI)-matched controls (CS).
Results: AD had ACTH and PRA higher and DHEAS lower (p<0.0005) than CS. Mean waist was higher (p<0.05) in AD than in CS. Although no differences were found for mean gluco-lipids levels, a higher percentage of AD compared to CS were IGT (8 vs 0%), hypercholesterolemic (18 vs 8%), and hypertriglyceridemic (18 vs 8%); none of the AD and CS showed either HDL<40 mg/dl or LDL>190 mg/dl. At the multiple regression analysis, in both AD and CS, BMI was the best predictor of 2-h glucose and age of total and LDL cholesterol; in AD, no significant correlation was found between the above mentioned metabolic parameters and either hormone levels or disease duration. In both AD and CS 24-h blood pressure and IMT were normal.
Conclusions: Our study shows a higher prevalence of central adiposity, impaired glucose tolerance and dyslipidemia in AD patients.
Similar articles
-
Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.Endocrine. 2016 Feb;51(2):360-8. doi: 10.1007/s12020-015-0681-z. Epub 2015 Jul 17. Endocrine. 2016. PMID: 26184416
-
BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease.Clin Endocrinol (Oxf). 2012 Dec;77(6):863-70. doi: 10.1111/j.1365-2265.2012.04439.x. Clin Endocrinol (Oxf). 2012. PMID: 22587831
-
[Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].Ann Acad Med Stetin. 2002;48:283-300. Ann Acad Med Stetin. 2002. PMID: 14601484 Clinical Trial. Polish.
-
Pulsatile luteinizing hormone secretion in patients with Addison's disease. Impact of glucocorticoid substitution.J Clin Endocrinol Metab. 1998 Mar;83(3):736-43. doi: 10.1210/jcem.83.3.4671. J Clin Endocrinol Metab. 1998. PMID: 9506718 Review.
-
Glucocorticoid replacement therapy in patients with Addison's disease.Expert Opin Pharmacother. 2007 Apr;8(6):725-9. doi: 10.1517/14656566.8.6.725. Expert Opin Pharmacother. 2007. PMID: 17425469 Review.
Cited by
-
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency.Front Endocrinol (Lausanne). 2023 Sep 11;14:1234237. doi: 10.3389/fendo.2023.1234237. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37766685 Free PMC article.
-
Cardiovascular risk factors in patients with Addison's disease: a comparative study of South African and Swedish patients.PLoS One. 2014 Mar 6;9(6):e90768. doi: 10.1371/journal.pone.0090768. eCollection 2014. PLoS One. 2014. PMID: 24603607 Free PMC article.
-
Generation of glucocorticoid-producing cells derived from human pluripotent stem cells.Cell Rep Methods. 2023 Nov 20;3(11):100627. doi: 10.1016/j.crmeth.2023.100627. Epub 2023 Nov 3. Cell Rep Methods. 2023. PMID: 37924815 Free PMC article.
-
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity.Endocr Rev. 2024 Jul 12;45(4):593-624. doi: 10.1210/endrev/bnae008. Endocr Rev. 2024. PMID: 38551091 Free PMC article. Review.
-
Glucocorticoid replacement therapy for primary and secondary adrenal insufficiency and their impact on cognition.Front Endocrinol (Lausanne). 2023 Mar 17;14:1153595. doi: 10.3389/fendo.2023.1153595. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37008924 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials